The brief
- Junevity silences transcription factors with siRNA to reprogram cell networks. Founders' PNAS study showed restoration of aging cells.
- Lead JUN_01 targets obesity and diabetes with twice-yearly dosing. Human trials planned H2 2026.
Technical approach
Target finding
ML finds transcription factors to reprogram
Combines human disease omics, genetic linkages and ML to identify transcription factors whose repression restores cell health.
Mechanism
siRNA silences the target gene
Antisense sequences match the target factor, triggering the cell's machinery to degrade and silence that gene.
Network reset
Silencing one hub restores multiple pathways
Transcription factors are master regulators controlling hundreds of genes. Silencing one restores multiple downstream pathways at once.
Dosing
Infrequent dosing due to sustained effects
Effect persists for months after dosing, allowing twice-yearly dosing instead of daily pills.
